Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL126761 | 0.92 | CES1 (0.36) | CES1CA1CA2CA9PLA2G2C | |
| SCHEMBL16288545 | 0.90 | CES1 (0.39) | CES1CA1CA2CA9PLA2G2C | |
| SCHEMBL124511 | 0.90 | CES1 (0.39) | CES1CA1CA2CA9PLA2G2C | |
| SCHEMBL16288356 | 0.90 | CES1 (0.39) | CES1CA1CA2CA9PLA2G2C | |
| SCHEMBL16288954 | 0.90 | CES1 (0.39) | CES1CA1CA2CA9PLA2G2C | |
| SCHEMBL16288749 | 0.90 | CES1 (0.39) | CES1CA1CA2CA9PLA2G2C | |
| SCHEMBL128568 | 0.83 | — | — | |
| SCHEMBL9076724 | 0.83 | CES1 (0.38) | CES1CA1CA2CA9PLA2G2C | |
| SCHEMBL15823328 | 0.80 | CES1 (0.46) | CES1CA1CA2CA9PLA2G2C | |
| SCHEMBL3837886 | 0.80 | CES1 (0.35) | CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111315828-B | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2023-09-29 | — | — | CN | disclosed |
| CN-112154167-B | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2023-08-22 | — | — | CN | disclosed |
| CN-107918247-B | Colored curable resin composition | 住友化学株式会社 | 2022-03-18 | — | — | CN | disclosed |
| CN-112154167-A | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2020-12-29 | — | — | CN | disclosed |
| CN-111315828-A | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2020-06-19 | — | — | CN | disclosed |
| WO-2020021969-A1 | COMPOSITION, CURED PRODUCT, OPTICAL FILTER, AND PRODUCTION METHOD FOR CURED PRODUCT | 株式会社ADEKA | 2020-01-30 | — | — | WO | disclosed |
| EP-2970146-B1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND (DE) | 2017-11-01 | — | — | EP | disclosed |
| EP-2909201-B1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND (DE) | 2017-02-22 | — | — | EP | disclosed |
| US-9388141-B2 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor | ABBVIE INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388148-B2 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor | ABBVIE INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-7053167-B2 | Silsesquioxane derivative having functional group | CHISSO CORPORATION (JP) | 2006-05-30 | — | — | US | disclosed |
| US-20060094849-A1 | Silicon compound | JNC CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060089504-A1 | Silsesquioxane derivative having functional group | ITO KENYA | 2006-04-27 | — | — | US | disclosed |
| EP-1650214-A2 | Silicon compound | CHISSO CORPORATION (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20050250925-A1 | Silicon compound | JNC CORPORATION (JP) | 2005-11-10 | — | — | US | disclosed |
| US-20050215807-A1 | Silsesquioxane derivative | JNC CORPORATION (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1550664-A1 | SILICON COMPOUND | CHISSO CORPORATION (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1544202-A1 | NOVEL HERBICIDES, USAGE THEREOF, NOVEL THIENOPYRIMIDINE DERIVATIVES, INTERMEDIATES OF THE SAME, AND PROCESS FOR PRODUCTION THEREOF | Nihon Nohyaku Co., Ltd. (JP) | 2005-06-22 | — | — | EP | disclosed |
| US-20040068074-A1 | Production process for silsesquioxane derivative having functional group and silsesquioxane derivative | JNC CORPORATION (JP) | 2004-04-08 | — | — | US | disclosed |
| US-20040030084-A1 | Production process for silsesquioxane derivative and silsesquioxane derivative | JNC CORPORATION (JP) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215807-A1 | Silsesquioxane derivative | STS, SFXN1, SULT1A1 | CES1 1338/4885CA1 116/4885CA2 308/4885 |
| US-20060089504-A1 | Silsesquioxane derivative having functional group | SFXN1, STS, SRM | CES1 2470/4885CA1 24/4885CA2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.